This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information
Home

Menu

Close

RTIs & Acute Otitis MediaUpper Respiratory Tract Infections (Upper RTIs)Acute Bacterial SinusitisPharyngitis/TonsillitisAcute Otitis MediaAcute Otitis MediaLower Respiratory Tract Infections (Lower RTIs)Community-Acquired PneumoniaAcute Bacterial Exacerbation of Chronic BronchitisSTIsSexually Transmitted Infections (STIs)Infections by Chlamydia trachomatisInfections by Neisseria gonorrhoeaeChancroid/Genital Ulcers MenSSTIsSkin and Soft-Tissue Infections (SSTIs)Uncomplicated Skin and Soft-Tissue InfectionsSafetySafetySafetyAdditional InformationAdditional InformationIndication and SusceptibilityFormulationsMode of ActionReconstitution of Powder for Oral Suspension for PediatricsPediatric AdministrationResourcesResourcesPrescribing InformationEventsMaterialsVideos

Skin and Soft-Tissue Infections  |  Uncomplicated Skin and Soft-Tissue Infections

Uncomplicated Skin and Soft-Tissue Infections

Administration

Pathogens

Epidemiology

Risk Factors

Efficacy

Administration

Adults1

500 mg once daily for 3 days, or an alternative of 500 mg on Day 1, then 250 mg daily on Days 2-5

  • ZITHROMAX should be given as a single daily dose1
  • ZITHROMAX tablets and suspension can be taken with or without food1
Renal Impairment1

No dose adjustment is necessary in patients with mild to moderate renal impairment (glomerular filtration rate [GFR] of 10–80 mL/min). Caution should be exercised when ZITHROMAX is administered to patients with severe renal impairment (GFR <10 mL/min)

Hepatic Impairment1

The same dosage as in patients with normal hepatic function may be used in patients with mild to moderate hepatic impairment

Pathogens

Main Bacterial Pathogens:

According to the SENTRY Antimicrobial Surveillance Program, which has monitored skin and soft-tissue infections (SSTIs) since 1997, Staphylococcus aureus is rated as the predominant pathogen in all regions across North America, Latin America, and Europe2

Other Pathogens Include:3

  • Group A Streptococcus spp.
  • Bacteroides spp.
  • Pseudomonas aeruginosa
  • Enterococcus
  • Enterobacteriaceae
  • Clostridium spp.
EpidemiologyLevels of antibiotic resistance in SSTIs are important among the causative agents for SSTIs:3-5

According to the Centers for Disease Control and Prevention in the US, approximately 30% of healthcare-associated Enterococcal infections* are vancomycin-resistant4

Data from the National Healthcare Safety Network in the US show that, in 2015, 16.5% of Enterobacteriaceae infections† were caused by Klebsiella and Escherichia coli isolates with the extended-spectrum beta lactamase, and the percentage of carbapenem-resistant Enterobacteriaceae infections was 3.1%5

Azithromycin is not active against Enterococcus.Enterobacteriaceae are inherently resistant to azithromycin.
Risk Factors3

Patient Related:

  • Critical illness
  • Elderly age
  • Immunocompromised state
  • Liver and kidney disease
  • Vascular (especially lymphatic or venous) insufficiency

Etiological:

  • Diabetes
  • Cirrhosis
  • Neutropenia
  • Bite wounds
  • Animal contact
  • Hot tub use
  • Freshwater/seawater exposure
  • Drug abuse
EfficacyZITHROMAX – Once daily over 3 days: an effective treatment for children with skin and soft-tissue infections6

Pathogens Eradicated*

Adapted from Montero L. 19966
*No statistically significant difference between groups in clinical efficacy

Montero et al. 19966
  • An open, multicenter, randomized study of either azithromycin once-daily for 3 days or cefaclor three-times-daily for 10 days in pediatric patients (6 months–12 years) with skin and/or soft-tissue infections
  • There were no significant between-group differences in clinical efficacy: at visit 3, patients considered cured or improved were 92/98 (94%) with azithromycin, and 93/98 (95%) with cefaclor. 95% of pathogens were eradicated with azithromycin, and 99% of pathogens with cefaclor
TitleZITHROMAX is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients.1
As with erythromycin and other macrolides, rare serious allergic reactions, including angioedema and anaphylaxis (rarely fatal), dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) (rarely fatal), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported.1
Use of ZITHROMAX should be undertaken with caution in patients with significant hepatic disease. Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure have been reported, some of which have resulted in death.1You might also be interested in...Resources ZITHROMAX® Mode of Action Find out more LoadingReferences:Pfizer Malaysia ZITHROMAX Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17705. Accessed January 2024.Bassetti M, et al. Clin Microbial Infect. 2014;20(Suppl. 4):3–18.Ki V, et al. Can J Infect Dis Med Microbial. 2008;19(2):173–84.CDC. Antibiotic Resistance Threats in the United States, 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed June 2023.Woodworth KR. MMWR Morb Mortal Wkly Rep. 2018;67(13):396-401.Montero L. J Antimicrob Chemother. 1996;37(Suppl. C):125–31.

Adults1

ZITHROMAX® Safety Information Find out more Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

PP-ZIT-MYS-0243-28FEB2024
You are now leaving the PfizerPro Malaysia website
​
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023